全文获取类型
收费全文 | 4746篇 |
免费 | 269篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 27篇 |
儿科学 | 426篇 |
妇产科学 | 141篇 |
基础医学 | 500篇 |
口腔科学 | 126篇 |
临床医学 | 278篇 |
内科学 | 1190篇 |
皮肤病学 | 132篇 |
神经病学 | 228篇 |
特种医学 | 139篇 |
外科学 | 689篇 |
综合类 | 178篇 |
一般理论 | 1篇 |
预防医学 | 176篇 |
眼科学 | 130篇 |
药学 | 246篇 |
中国医学 | 20篇 |
肿瘤学 | 401篇 |
出版年
2023年 | 29篇 |
2022年 | 69篇 |
2021年 | 163篇 |
2020年 | 82篇 |
2019年 | 133篇 |
2018年 | 160篇 |
2017年 | 116篇 |
2016年 | 154篇 |
2015年 | 145篇 |
2014年 | 191篇 |
2013年 | 255篇 |
2012年 | 388篇 |
2011年 | 371篇 |
2010年 | 223篇 |
2009年 | 171篇 |
2008年 | 284篇 |
2007年 | 299篇 |
2006年 | 252篇 |
2005年 | 209篇 |
2004年 | 191篇 |
2003年 | 154篇 |
2002年 | 169篇 |
2001年 | 92篇 |
2000年 | 110篇 |
1999年 | 78篇 |
1998年 | 44篇 |
1997年 | 32篇 |
1996年 | 27篇 |
1995年 | 23篇 |
1994年 | 26篇 |
1993年 | 18篇 |
1992年 | 39篇 |
1991年 | 51篇 |
1990年 | 30篇 |
1989年 | 42篇 |
1988年 | 26篇 |
1987年 | 27篇 |
1986年 | 16篇 |
1985年 | 17篇 |
1984年 | 16篇 |
1983年 | 14篇 |
1982年 | 7篇 |
1981年 | 7篇 |
1980年 | 7篇 |
1979年 | 6篇 |
1977年 | 5篇 |
1976年 | 13篇 |
1974年 | 5篇 |
1972年 | 7篇 |
1971年 | 5篇 |
排序方式: 共有5028条查询结果,搜索用时 187 毫秒
1.
Diane C. Ling Bryanna L. Moppins Colin E. Champ Vikram C. Gorantla Sushil Beriwal 《Practical radiation oncology》2021,11(1):e30-e35
PurposeRegional nodal irradiation (RNI) improved disease-free survival by 3% to 5% in 2 large randomized trials, but this small absolute advantage relies on accurate contouring and dose delivery. We audited our network to determine compliance on regional nodal coverage, contouring, and dosimetric parameters with respect to accepted guidelines.Methods and MaterialsIn our network, we have established a clinical pathway for patients with node-positive breast cancer that guides indications for RNI and dosimetric goals. We reviewed records of 183 patients with nodal macrometastases after upfront surgery or involved nodes of any size after neoadjuvant chemotherapy. Radiation treatment plans were examined to determine lymph node volumes treated, whether nodes were contoured, quality of nodal contours, and whether target coverage and normal organ dosimetric constraints were met when RNI was delivered.ResultsDespite the presence of macrometastases on sentinel lymph node biopsy, no lymph nodes were treated in 2.2% (4 of 183). Of 179 patients who received nodal irradiation, 18 received radiation to axillary levels 1 and 2 only, and 161 patients received RNI. Overall, regional nodes were not treated despite strong indications in 7.6% (14 of 183). Treated nodes were not contoured for 2.2% (4 of 179), and lymph node contours were unacceptable in 15.4% (27 of 175). Of patients receiving RNI, 14.9% (24 of 161) did not have adequate nodal target volume coverage, mean heart dose was >4 Gy for 3.1% (5 of 161), and lung V20 Gy was >35% for 8.7% (14 of 161).ConclusionsAdherence to indications for regional nodal treatment was high, but nodes were either not contoured or had unacceptable contour quality in 18% of plans, and coverage was inadequate in 15%. Because the small disease-free survival advantage seen in trials may be decreased with these deviations, routine clinical practice requires detailed peer review to fully translate results of clinical trials. 相似文献
2.
Sameer Arora Kamal Shemisa Muthiah Vaduganathan Arman Qamar Ankur Gupta Sushil K. Garg Dharam J. Kumbhani Helen Mayo Houman Khalili Ambarish Pandey Sandeep R. Das 《Journal of the American College of Cardiology》2019,73(19):2454-2464
Ticagrelor is a cornerstone of modern antithrombotic therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary intervention. Adverse effects such as bleeding and dyspnea have been associated with premature ticagrelor discontinuation, which may limit any potential advantage of ticagrelor over clopidogrel. The randomized trials of ticagrelor captured adverse events, offering the opportunity to more precisely quantify these effects across studies. Therefore, a meta-analysis of 4 randomized clinical trials of ticagrelor conducted between January 2007 and June 2017 was performed to quantify the incidence and causes of premature ticagrelor discontinuation. Among 66,870 patients followed for a median 18 months, premature ticagrelor discontinuation was seen in 25%; bleeding was the most common cause of discontinuation followed by dyspnea. Versus the comparators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4-fold higher, the relative risk of bleeding was 3.2-fold higher, and the relative risk of discontinuation due to any adverse event was 59% higher for patients receiving ticagrelor. Understanding these potential barriers to adherence to ticagrelor is crucial for informed patient-physician decision making and can inform future efforts to improve ticagrelor adherence. This review discusses the incidence, causes, and biological mechanisms of ticagrelor-related adverse effects and offers strategies to improve adherence to ticagrelor. 相似文献
3.
4.
Surender Kumar Yachha Rakesh Aggarwal S Srinivas Anshu Srivastava Sanjay K Somani Srivenu Itha 《Indian journal of gastroenterology》2006,25(3):132-135
BACKGROUND: We prospectively evaluated the usefulness of IgA tissue transglutaminase antibodies (IgA tTG) in the initial diagnosis of celiac disease (CD) and compared its diagnostic potential with that of IgA anti-endomysial antibodies (IgA EMA) and anti-IgA and IgG gliadin antibodies (AGA and AGG, respectively). METHODS: Sera of 23 untreated children fulfilling the revised ESPGHAN criteria for diagnosis of CD (Group I; mean age 10.8 y); 19 disease controls (Group II; mean age 8.5 y) presenting with chronic diarrhea, short stature or both; and 22 healthy children (Group III; mean age 8.8 y) were studied. These were tested in a blinded manner for AGA, AGG, IgA tTG (guinea pig as antigen) and IgA EMA. RESULTS: In Group I, IgA EMA was positive in 19, IgA tTG in 17, AGA in 14 and AGG in 17 patients. In Group II, these tests were positive in 1, 0, 2 and 14 patients, respectively and in Group III, in 0, 0, 0 and 1 child, respectively. Analyzing data from Group I and II, IgA EMA, IgA tTG, AGA and AGG had sensitivity rates of 83%, 74%, 61% and 74%, respectively; the specificity rates were 95%, 100%, 89% and 26%; positive predictive values were 95%, 100%, 88% and 55% and negative predictive values were 82%, 74%, 65% and 45%, respectively. CONCLUSION: IgA tTG is useful for the diagnosis of CD, with sensitivity and specificity rates comparable to those of EMA and this test is well suited for use in tropical countries like India. 相似文献
5.
6.
P Aggarwal S K Sharma A B Dey T K Chattopadhyay M Mathur 《Postgraduate medical journal》1989,65(770):929-931
A case of malignant fibrous histiocytoma of the mediastinum presenting with unusual features of fever and leucocytosis is reported. This is the youngest patient reported in the literature who had this tumour in the mediastinum. 相似文献
7.
8.
9.
Dhawan Subhash; Puri Raj K.; Kumar Ashok; Duplan Helen; Masson Jean-Michel; Aggarwal Bharat B. 《Blood》1997,90(4):1535-1544
10.
Synthesis and biological evaluation of prodrugs of zidovudine 总被引:4,自引:0,他引:4
A series of prodrugs of zidovudine (AZT) has been synthesized in an effort to enhance the uptake of the prodrugs by the HIV-1 infected cells and to increase the plasma half-life of AZT. The 5'-OH function of AZT was esterified with various acids in the presence of DCC and 4-(dimethylamino)pyridine (DMAP). The prodrug moieties included (a) morpholine and N-phenylpiperazine-1-acetic acid, (b) 1,4-dihydro-1-methyl-3-nicotinic acid, (c) retinoic acid, and (d) certain amino acids. The anti-HIV-1 activity of the esters was determined in peripheral blood lymphocytes. The IC50 for AZT in this system was 0.12 microM whereas for prodrugs it ranged from 0.05 to 0.2 microM. The prodrugs were generally less cytotoxic than AZT except the retinoic acid ester. In vitro hydrolysis of the various esters in human plasma indicated that these agents were relatively stable toward plasma esterases with t1/2 ranging from 10 to 240 min. Drug uptake studies in H9 cells with radiolabeled analogues demonstrated that the retinoic acid ester achieved approximately 4-fold higher intracellular concentration than [3H]AZT. However, 1,4-dihydro-1-methyl-3-[(pyridylcarbonyl)oxy] ester (5) was the most active agent of this series and had a higher therapeutic index than AZT. 相似文献